Larry Ellison’s AI vision ranges from cancer claims to a robot tax

At Oracle AI World, Larry Ellison argued that AI could reshape healthcare and the economy, while outlining Oracle Health modules planned for early next year. His most eye-catching predictions are not the same thing as delivered products, a distinction worth keeping firmly in view.

Oracle Watch analysis

What happened

Ellison told Diginomica that AI could help make most cancers disappear within five to ten years, and suggested that governments may need to tax value created by robots rather than relying on taxes on human labour. He also argued that AI could help distribute drugs more widely and make healthcare cheaper. These are Ellison’s predictions and proposals, not established medical or economic outcomes.

On Oracle’s products, Ellison described healthcare modules on the company’s release schedule for early next year. He said a hospital using Epic could switch on Oracle’s oncology module without migrating data or retraining staff. He also pointed to plans for automated prior authorisation and a patient portal that brings together records across US hospital systems. Diginomica disclosed that Oracle was a partner at the time of publication.

Why it matters

There are two distinct stories here: a sweeping view of what AI might do to healthcare and society, and nearer-term claims about what Oracle Health intends to offer. The first invites debate; the second gives healthcare buyers concrete promises to measure against when the modules arrive.

Ellison’s cancer timeline is a striking prediction, not evidence that cancer will be cured on that schedule. Likewise, the account of a hospital switching on a module with no data migration or new training is a claim about a proposed product, not a reported deployment result.

Our read

The big vision is a lively keynote, but the useful test is delivery. Oracle’s promises about interoperability and implementation are specific enough to check against real customer experience next year. Until then, keep the forecast in the forecast column, where it belongs.

What to watch

• Whether the healthcare modules become available on the stated early-next-year schedule.
• Whether hospitals can use the oncology module without data migration or new training.
• What evidence Oracle provides for its clinical-trial, prior-authorisation and patient-portal plans.
• Whether Ellison’s predictions translate into measurable healthcare outcomes, rather than memorable stage lines.

Discussion spark: Should AI healthcare companies be judged mainly on ambitious long-term promises, or on whether their near-term products work in real hospitals?

not affiliated with or endorsed by Oracle